🚨 Funding announcement! 🚨 Proud to co-lead Sakana AI's over $100M Series A with New Enterprise Associates (NEA) and Khosla Ventures! Sakana AI is pioneering nature-inspired AI, and we're excited to support their new collaboration with NVIDIA on AI research and infrastructure in Japan 🐟 🔗 https://lnkd.in/dPhFENRt
Lux Capital
Venture Capital and Private Equity Principals
New York, NY 31,670 followers
We invest in emerging science and technology ventures that turn sci-fi to sci-fact.
About us
Lux Capital is a venture capital firm investing in emerging science and technology at the outermost edges of what is possible. They partner with iconoclastic inventors who challenge the status quo and the laws of nature to bring their futuristic ideas to life. Over the past two decades, Lux has expanded from its New York City roots to Silicon Valley, and built a $5+ billion AUM firm of more than 30 full-time professionals, with a wide spectrum of technical backgrounds and the versatility to invest at any stage. Press inquiries: [email protected].
- Website
-
https://www.luxcapital.com/
External link for Lux Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2000
- Specialties
- venture capital, startups, entrepreneurs, emerging technologies, science, and deep tech
Locations
-
Primary
920 Broadway
11th Floor
New York, NY 10010, US
-
1600 El Camino Real
Suite 290
Menlo Park, CA 94025, US
Employees at Lux Capital
-
Shahin Farshchi
General Partner at Lux Capital. Brain-chip designer, founder, pilot, car enthusiast, trekkie, dad, Bear, and Bruin
-
Scott Rubin
Chief Marketing Officer at Lux Capital
-
Bilal Zuberi
General Partner at Lux Capital. Cross-sector seed to growth stage. $5B+ AUM.
-
Robert Paull
Co-Founder & Venture Partner, Lux Capital
Updates
-
🚨 Funding announcement! 🚨 We're thrilled to lead eGenesis, Inc. $191M Series D round, accelerating their groundbreaking work in kidney transplants. A major step toward transforming organ transplantation! #biotech #xenotransplantation More here: https://lnkd.in/dU6QT-3E
eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
businesswire.com
-
Lux Capital reposted this
Inspired by Lux Capital, EvolutionaryScale, and Enveda Biosciences's second annual Bio x ML Hackathon, powered by Amazon Web Services (AWS). Once again, this Hackathon will bring together the top minds in science and AI to advance human health, progress knowledge, and uncover solutions to challenging, unsolved problems in biology... Apply by Sept 22nd! https://hackathon.bio/ Thanks to: Tracie Rotter Eric Zimmerman Tess van Stekelenburg Matthew Nemeth #AWSstartups #innovation #advancinghumanhealth 🌿 ✨ 🚀
We're back! Lux Capital is running a Bio x ML Hackathon with EvolutionaryScale and Enveda Biosciences Bio from Oct 10-20! By bringing together the world’s top minds, we’re driving forward the next frontier of science with AI-driven tools and scientific imagination. Build on top of the latest foundation models like ESM3 (98B parameters, GPU access) and proprietary datasets to predict protein activity, model across therapeutic modalities, and develop next-gen biology applications. Model APIs, datasets & compute powered by Amazon Web Services (AWS), OpenAI, NVIDIA, DigitalOcean, EvolutionaryScale, Modal, LatchBio, Together AI, Enveda Biosciences, and RunPod. Open globally. Get started here: hackathon.bio
-
-
We're back! Lux Capital is running a Bio x ML Hackathon with EvolutionaryScale and Enveda Biosciences Bio from Oct 10-20! By bringing together the world’s top minds, we’re driving forward the next frontier of science with AI-driven tools and scientific imagination. Build on top of the latest foundation models like ESM3 (98B parameters, GPU access) and proprietary datasets to predict protein activity, model across therapeutic modalities, and develop next-gen biology applications. Model APIs, datasets & compute powered by Amazon Web Services (AWS), OpenAI, NVIDIA, DigitalOcean, EvolutionaryScale, Modal, LatchBio, Together AI, Enveda Biosciences, and RunPod. Open globally. Get started here: hackathon.bio
-
-
Why have algorithms not upended venture capital? Dario Soatto explains in his first column for the Riskgaming newsletter:
My first piece for Lux Capital. TLDR: In high-noise environments, simple algorithms usually beat human predictions, but VC power laws make algorithmic prediction hard, allowing the best and most well-connected VCs to achieve persistent returns.
The Broken Leg Problem of VC
Dario Soatto on LinkedIn
-
Lux Capital reposted this
Co-founder and Managing Partner of Lux Capital Josh Wolfe is a master at understanding complex, emerging technologies. In our conversation, Josh shared how he identifies the next big thing, his contrarian views on nuclear energy, biotech, and robotics, as well as his thoughts on the state of the venture capital market today. Here are some key takeaways: → Obsessions Fuel Breakthroughs Josh often dives deep into a particular technology for many weeks, even years, juggling 10-12 of these obsessions at once. For example, his decade-long focus on using technology to replicate and understand smells seemed fruitless for years until the right technological breakthrough occurred. When you believe something is inevitable but aren’t sure of the timeline, continuing to pursue an idea can eventually lead to big rewards when timing and technology align. → How Josh Masters New Domains Josh dives deep into scientific research (not just page one) to quickly become knowledgeable in new fields, and he connects with top scientists to learn about breakthroughs before they’re public. By the time he talks to experts, he’s already well-informed, allowing him to spot trends early and make investment decisions off the beaten path. For example, when the venture world was fixated on solar, wind, and biofuels, Josh turned his attention to his well-informed thesis on nuclear energy. → De-Risking Investments to Maximize Returns Josh Wolfe emphasizes the importance of de-risking early investments by identifying key risks to the business and providing resources to mitigate them. Later investors will then be willing to pay a higher price because they face less uncertainty. His approach is not about being contrarian for its own sake, but about being ahead of the curve (much like moving to Brooklyn before it became mainstream). You want others to agree with you, just later. → Josh’s Harsh Take on the Future of VC Josh predicts that 30-50% of venture firms may not survive the next few years, particularly those that are unable to adapt to changing market dynamics. Josh believes the firms that will thrive are those that can be nimble, make smart capital allocations, and avoid the pitfalls that come from following the herd in overhyped sectors. More insights for anyone in tech or venture capital in the full episode: https://lnkd.in/dgxR4fMr
Josh Wolfe (Lux Capital): Predictions on Emerging Technologies, AI, and the Future of VC
-
Lux MBA summer intern Bradley Aka shared his thoughts on digital twins and how they can be implemented to transform healthcare in his latest piece below. Check it out:https://lnkd.in/eazMG3nf
Digital Twins In Healthcare
Bradley Aka on LinkedIn
-
The latest edition of our Riskgaming newsletter arrives via Sri Lankan writer Yudhanjaya Wijeratne on why some regions have incredibly dynamic scientific and engineering innovation — and others don't.
Riskgaming: Hacking Priomoridal Soups
Lux Capital on LinkedIn
-
Lux Capital reposted this
A week after giving birth to my third child last September, I was preparing to take our first walk around the neighborhood, when I was hit with the worst headache of my life. Fifteen minutes later--and thanks to quick triage from Maven Clinic's Neel Shah, I found myself going over my will on the way to the hospital, where I would stay under intensive care and stroke and seizure watch for the next five days. Thank you to Emma Hinchliffe for sharing more about my harrowing experience with rare and often deadly postpartum preeclampsia in Fortune's Broadsheet today--and how it has re-invigorated my passion for women's health innovation and investment.
Deena Shakir was eight days postpartum with her third child last September when she got a bad headache. Just over a week after a C-section, Shakir still didn’t think her headache was an emergency. After going to the hospital, Shakir stayed there for five days; it took three days for her blood pressure to stabilize. If she’d arrived 30 minutes later, a nurse told her, she’d likely have had a fatal stroke. She almost couldn’t believe that after spending years becoming an expert in women’s health, she’d come so close to dying after childbirth. For Shakir, the experience reinforced why she invests in women’s health companies. “A lot of my investments are trying to democratize everyone to have access to healthcare in your pocket,” she says. “In this case, it’s literally the difference between life and death.” Read more here: bit.ly/4dul37p
-
-
Lux Capital reposted this
General Partner at Lux Capital. Brain-chip designer, founder, pilot, car enthusiast, trekkie, dad, Bear, and Bruin
The future of the chip economy hinges on an extraordinary amount of manpower and brainpower required to design tomorrow's chips, and their rapidly spiraling costs. In this article, we explore how AI can change that:
A Looming Labor Crisis in Chip Design
Shahin Farshchi on LinkedIn